48 citations
,
April 2021 in “Journal of the American Academy of Dermatology” This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.
19 citations
,
December 2019 in “Journal of the American Academy of Dermatology” This study suggests that intralesional triamcinolone acetonide at a concentration of 5 mg/mL may offer the best balance of effectiveness and safety for treating focal alopecia areata.
16 citations
,
May 2017 in “American Journal of Clinical Dermatology” This review discusses the clinical features, diagnosis, and treatment options for alopecia areata of the beard and reports no new clinical results.
22 citations
,
May 2017 in “Journal of dermatological treatment” This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” This review identifies shared interferon gamma-driven immune pathways in vitiligo and alopecia areata, revealing potential targets for new treatments, but reports no clinical results.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
50 citations
,
July 2015 in “Journal of the American Academy of Dermatology” This study found that 2.5 mg/mL triamcinolone acetonide injections were as effective as higher doses for treating limited, patchy alopecia areata, while minimizing side effects like skin atrophy.
18 citations
,
January 2015 in “International Journal of Trichology” This study found that intralesional steroid treatment led to significantly more hair regrowth in alopecia areata patients than narrow band ultraviolet B therapy, while their combination did not enhance effectiveness.
25 citations
,
February 2014 in “British journal of dermatology/British journal of dermatology, Supplement” The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.
67 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
36 citations
,
May 2011 in “Dermatologic therapy” This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.
48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
244 citations
,
January 2010 in “Journal of the American Academy of Dermatology” This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.
17 citations
,
October 2009 in “Dermatology” This study reported that ultraviolet light treatment from a Kromayer lamp stimulated hair growth in four out of six patients with alopecia, whereas intralesional triamcinolone acetonide had a mixed effect.
34 citations
,
March 2007 in “Biochemical and Biophysical Research Communications” This study suggests that decreased expression of thioredoxin reductase 1 in hair follicle cells may contribute to glucocorticoid resistance in some alopecia areata patients by affecting the intracellular redox system.
100 citations
,
July 2006 in “British Journal of Dermatology” This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.
17 citations
,
December 2001 in “Dermatologic therapy” This review discusses various treatment options for alopecia areata tailored by age and severity, providing a practical algorithm, but reports no new clinical results.
118 citations
,
April 1998 in “Dermatologic Clinics” This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.
11 citations
,
April 1997 in “International Journal of Dermatology” This article discusses using topical tretinoin with intralesional triamcinolone acetonide for alopecia areata in northern Saudi Arabia, but it reports no new clinical findings.
15 citations
,
June 1961 in “Archives of Dermatology” This report details observations from four patients with alopecia areata who received intralesional triamcinolone injections to assess its effectiveness for promoting hair regrowth in localized areas.
57 citations
,
December 1960 in “Archives of Dermatology” This introduction reviews historical use of steroids for alopecia treatment, mentioning early cases of hair regrowth with cortisone acetate but provides no new clinical data.
